Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI Cancers

Marios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.

Related Keywords

China ,United States ,Marios Giannakis ,Dana Farber Cancer Institute ,Harvard Medical School ,Gastrointestinal Cancer Center ,Onclive Tv ,Gastrointestinal Cancer ,Pembrolizumab ,Gx1321 ,